Skip to main content
. Author manuscript; available in PMC: 2020 Dec 11.
Published in final edited form as: Oncogene. 2020 Oct 8;39(49):7166–7180. doi: 10.1038/s41388-020-01488-5

Figure. 1.

Figure. 1.

Depletion of SHP2 inhibits the growth of metastatic breast cancer cells. a, b Immunoblot analyses with quantification for SHP2 in 4T1 and D2.A1 cells stably expressing three independent doxycycline-inducible shRNA sequences targeting PTPN11 with and without doxycycline induction, compared with a scrambled (scram) shRNA control. c Quantification of SHP2 depletion for each shRNA construct in 4T1 and D2.A1 cells (n=3). Depletion efficiency was defined as the percentage of SHP2 protein decrease normalized to scramble controls upon doxycycline induction. d Schematic representation of 2D and 3D growth conditions. e 2D growth assays showing differential cell viability of 4T1 and D2.A1 cells upon doxycycline-induced depletion of SHP2. Data are the mean ± s.e.m. of two biological replicates completed in triplicate. f Representative photos showing 3D morphologies of 4T1 and D2.A1 cells upon depletion of SHP2. g Quantification of differential cell viability of 4T1 and D2.A1 cells upon depletion of SHP2. Data are shown as mean ± s.e.m. (n = 3 for 4T1; *p < 0.05; n = 4 for D2.A1, **p<0.01)